Biotechnology

ZHIFEI-BIOL

ZHIFEI-BIOL released FY2025 Q4 earnings on April 27 After-Market (BJT), actual revenue CNY 1.331 B (forecast CNY 3.126 B), actual EPS CNY -5.6459 (forecast CNY -2.3802)

ZHIFEI-BIOL released FY2026 Q1 earnings on April 27 During-Market (BJT), actual revenue CNY 2.15 B (forecast CNY 2.37 B), actual EPS CNY -0.1622 (forecast CNY -0.04)

ZHIFEI-BIOL released FY2025 Annual Earnings on April 27 After-Market (BJT), actual revenue CNY 8.958 B (forecast CNY 15.29 B), actual EPS CNY -6.1506 (forecast CNY -1.3082)

ZHIFEI-BIOL to release FY2025 earnings on April 28 After-Market (BJT), forecast revenue CNY 15.29 B, EPS CNY -1.3082

ZHIFEI-BIOL to release FY2026 Q1 earnings on April 28 during market hours (BJT), forecast revenue CNY 2.37 B, EPS CNY -0.04

ZHIFEI-BIOL released FY2025 9 Months Earnings on October 29 During-Market (BJT), actual revenue CNY 7.627 B, actual EPS CNY -0.504

ZHIFEI-BIOL released FY2025 Q3 earnings on October 29 During-Market (BJT), actual revenue CNY 2.708 B (forecast CNY 3.212 B), actual EPS CNY -0.2546 (forecast CNY 0.0382)

ZHIFEI-BIOL to Release FY2025 Q3 Earnings on October 30 During-Market (BJT), Forecast Revenue CNY 3.212 B, EPS CNY 0.0382

ZHIFEI-BIOL released FY2025 Semi-Annual Earnings on August 18 After-Market (BJT), actual revenue CNY 4.898 B, actual EPS CNY -0.2584

ZHIFEI-BIOL released FY2025 Q2 earnings on August 18 After-Market (BJT), actual revenue CNY 2.545 B (forecast CNY 3.677 B), actual EPS CNY -0.1219 (forecast CNY 0.0856)

Changfei Biologics Subsidiary Completes First National Inoculation of Quadrivalent Influenza Vaccine

ZHIFEI-BIOL FY2025 Semi-Annual Earnings Release on August 19, 2025 (BJT)

ZhiFei BioPharm leads decline in biotech sector, investing in new R&D

Investor Asks Chongqing Zhifei Biological About Vaccine R&D and Innovative Drug Layout

Changfei Bio Obtains mRNA-Related Patent

Changfei Bio and Subsidiaries Obtain Patent Certificate

ZhiFei Bio-Pharm Faces Financial Crisis with Stock Price at a New Low

ZhiFei Bio Nine-Valent HPV Vaccine Promotion, Financial Pressure Intensifies

Changfei Bioacquires Patent for Helicobacter Pylori Recombinant Vaccine

ZhiFei Bio Plunges Due to Strategic Mistakes

SBIO

300122

Zhifei Biological has signed a revised supply, distribution, and co-promotion agreement with Merck, effective April 2, 2026. This agreement aims to enhance strategic cooperation and market coordination, covering products like the nine-valent HPV vaccine until the end of 2028, with a possible two-year extension. Zhifei will adjust procurement based on market demand, with no base procurement amount specified. Both companies will negotiate procurement plans based on demand forecasts and vaccination rates, confirming details through written orders.

CoinLive

SPDR S&P Biotech

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

iShares US Pharma

VanEck Biotech ETF

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

Merck

VG Health

Invesco Biotechnology & Genome ETF

Zhifei Biological and Merck Sign Revised Agreement to Enhance Strategic Cooperation

ZHIFEI-BIOL: The improved Ankara strain vaccinia virus (MVA) monkeypox live attenuated vaccine has received clinical trial approval notification

Wallstreetcn

ZHIFEI-BIOL: The recombinant varicella-zoster virus ZFA01 adjuvanted vaccine (CHO cells) has received the clinical trial approval notice

ZHIFEI-BIOL expects a net loss attributable to shareholders of the listed company of RMB 10.6979361 billion to RMB 13.7256538 billion in 2025, compared to a profit of RMB 2.0184785 billion in the previous year

ZHIFEI-BIOL: CA111 injection has entered Phase I clinical trials

According to the Zhitong Finance APP, ZHIFEI-BIOL released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 7.627 billion yuan, a year-on-year decrease of 66.53%. The net loss attributable to shareholders of the listed company was 1.206 billion yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 1.227 billion yuan. The basic loss per share was 0.504 yuan

Zhitong

ZHIFEI-BIOL released its performance for the first three quarters, with a net loss attributable to the parent company of 1.206 billion yuan

ZHIFEI-BIOL's wholly-owned subsidiary ZHIFEI Longke Ma has developed a split influenza virus vaccine that has received the drug registration certificate from the National Medical Products Administration. This vaccine is suitable for individuals aged 32 and above and is used to prevent infectious diseases caused by the influenza virus. It is one of the main products for influenza prevention both domestically and internationally. The registered trivalent influenza vaccine, along with the quadrivalent influenza vaccine already approved by the company and other products under research, forms a rich series of influenza vaccines

ZHIFEI-BIOL: The company's self-developed influenza virus split vaccine has obtained a drug registration certificate

ZHIFEI-BIOL's subsidiary, Chen'an Biotech, has received clinical trial approval from the National Medical Products Administration for its CA111 injection, allowing trials to be conducted in overweight or obese adult patients. CA111 is a dual agonist that targets GIP and GLP-1 receptors, aimed at improving blood glucose control and weight loss through a synergistic mechanism

ZHIFEI-BIOL: CA111 injection has received approval for clinical trials

ZHIFEI-BIOL(300122.SZ)